Phase 1 PK Study of Ibuzatrelvir in Healthy Adults, Apr 27 2026
Summary
ClinicalTrials.gov registered a Phase 1 pharmacokinetic study (NCT07552779) for ibuzatrelvir, an oral COVID-19 study drug. The open-label study will enroll healthy adults who will stay approximately 9 nights and 10 days in a clinical research unit over an 11-week total study period. The trial will compare blood levels of ibuzatrelvir following administration of two different film-coated tablet formulations, including comparisons with and without food and with tablets dispersed in water.
“The goal of this clinical trial is to compare how much of the study drug ibuzatrelvir is in participants' blood after taking one of the two different types of tablets containing the same amount of ibuzatrelvir without food.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
ClinicalTrials.gov added a new Phase 1 study (NCT07552779) for ibuzatrelvir, an oral antiviral being investigated for COVID-19. The study will enroll healthy adults and assess how much of the drug enters the bloodstream after taking one of two different film-coated tablet formulations, with additional comparisons involving food intake and tablet dispersion in water.
Sponsors and clinical research organisations conducting antiviral development programmes should note this study as it reflects continued Phase 1 activity for oral COVID-19 therapeutics. Sites with capacity for Phase 1 pharmacokinetic units may wish to monitor enrollment progress for competitive landscape awareness.
Archived snapshot
Apr 28, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of How Ibuzatrelvir is Taken up Into the Blood of Healthy Adults After Taking Different Tablets of Ibuzatrelvir
Phase 1 NCT07552779 Kind: PHASE1 Apr 27, 2026
Abstract
Healthy adults will be enrolled into this open-label, Phase 1 research study. Participants will spend about 9 nights and 10 days in the clinical research unit (CRU) and the total time in the study will be about 11 weeks.
The goal of this clinical trial is to compare how much of the study drug ibuzatrelvir is in participants' blood after taking one of the two different types of tablets containing the same amount of ibuzatrelvir without food. The study will also measure how much ibuzatrelvir is in participants' blood after taking one type of the tablets dispersed in water and when one type of the tablets is taken with food. This study drug is taken by mouth.
Conditions: Coronavirus Disease 2019, Coronavirus Disease 2019 (COVID-19), COVID-19 (Coronavirus Disease 2019), Upper Respiratory Tract Infections, Respiratory Tract Infection, Respiratory Tract Diseases, COVID-19, COVID-19 Infection, COVID-19 SARS-CoV-2 Infection, Pneumonia, Lung Diseases
Interventions: Ibuzatrelvir co-process API film coated tablet, Ibuzatrelvir filmcoated tablet
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.